Exposure-response relationships of venetoclax in combination with carfilzomib and dexamethasone in relapsed/refractory t(11;14) multiple myeloma patients
Investigational New Drugs · 2024
DOI: 10.1007/s10637-024-01471-x ↗Kurz gefasst
Klinische Studie (Phase II) in der Zeitschrift Investigational New Drugs, 2024. Verfasst von Mohamed Ali Badawi und 6 weiteren Autor:innen. Beteiligte Einrichtung: Clinical Pharmacology, AbbVie Inc, 1 North Waukegan Road, North Chicago, IL, 60064-1802, USA. mohamed.badawi@abbvie.com. Hauptthemen laut MEDLINE: Multiple Myeloma, Dexamethasone, Bridged Bicyclo Compounds, Heterocyclic, Sulfonamides. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 38 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: AbbVie, Genentech.
Abstract (Originalsprache)
Venetoclax is a first in class BCL-2 inhibitor, currently under investigation for the treatment of t(11;14) multiple myeloma (MM). The objective of this analysis was to characterize the exposure-efficacy and exposure-safety relationships of venetoclax when combined with carfilzomib and dexamethasone (VenKd) in t(11;14)-positive relapsed or refractory (R/R) MM patients from a phase 2 study. Fifty-seven patients receiving VenKd or Kd were included in the analysis. Efficacy endpoints included progression-free survival and clinical response rates of overall response, very good partial response or better and complete response or better. Grade ≥ 3 neutropenia, Grade ≥ 3 infections, Grade ≥ 3 treatment-emergent adverse events and any grade serious treatment-emergent adverse events were evaluated. The analysis demonstrated that adding venetoclax to Kd resulted in increased ORR, ≥VGPR and ≥ CR rates compared to the control arm. Within the venetoclax treatment arms (VenKd), no significant exposure-efficacy relationships were observed for ORR and ≥ VGPR rates. Higher ≥ CR rates trended with higher venetoclax exposures. While both 400 mg and 800 mg venetoclax in VenKd arms were generally tolerated, higher rates of Grade ≥ 3 neutropenia were observed with higher venetoclax exposures. Higher venetoclax exposures however were not associated with increased rates of Grade ≥ 3 treatment-emergent adverse events, Grade ≥ 3 infections, or serious treatment-emergent adverse events (any grade). These results confirm the benefit of adding venetoclax to carfilzomib and dexamethasone and support continued evaluation of venetoclax 400-800 mg once daily in this combination in t(11;14)-positive R/R MM patients. NCT02899052 registered April 18, 2017.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Clinical Pharmacology, AbbVie Inc, 1 North Waukegan Road, North Chicago, IL, 60064-1802, USA. mohamed.badawi@abbvie.com.
- Clinical Pharmacology, AbbVie Deutschland GmbH & Co. KG, Ludwigshafen am Rhein, Germany.
- Oncology Development, AbbVie, Pharmacyclics, Schaffhausen, Switzerland.
- Genentech, Inc, South San Francisco, CA, USA.
- Winship Cancer Institute of Emory University, Emory University, Atlanta, GA, USA.
- Clinical Pharmacology, AbbVie Inc, 1 North Waukegan Road, North Chicago, IL, 60064-1802, USA.
Förderung
- AbbVie
- Genentech
Zitieren
APA
Badawi, M. A., Engelhardt, B., Dobkowska, E., Deng, R., Kaufman, J. L., Menon, R., & Salem, A. H. (2024). Exposure-response relationships of venetoclax in combination with carfilzomib and dexamethasone in relapsed/refractory t(11;14) multiple myeloma patients. Investigational New Drugs. https://doi.org/10.1007/s10637-024-01471-x
Vancouver
Badawi MA, Engelhardt B, Dobkowska E, Deng R, Kaufman JL, Menon R, et al. Exposure-response relationships of venetoclax in combination with carfilzomib and dexamethasone in relapsed/refractory t(11;14) multiple myeloma patients. Investigational New Drugs. 2024. doi:10.1007/s10637-024-01471-x
BibTeX
@article{Badawi2024,
author = {Badawi, Mohamed Ali and Engelhardt, Benjamin and Dobkowska, Edyta and Deng, Rong and Kaufman, Jonathan L and Menon, Rajeev and Salem, Ahmed Hamed},
title = {Exposure-response relationships of venetoclax in combination with carfilzomib and dexamethasone in relapsed/refractory t(11;14) multiple myeloma patients},
journal = {Investigational New Drugs},
year = {2024},
doi = {10.1007/s10637-024-01471-x}
}
EUVIMED